MRI靶向活检检出的GG2前列腺癌与系统活检检出的GG1复发风险相当
该回顾性研究比较了系统活检检出的GG1前列腺癌(n=3317)与MRI靶向活检检出的GG2前列腺癌(n=554)的根治性治疗风险和复发风险。结果显示GG1组中位至治疗时间显著更长(31个月 vs 4个月,P<0.0001),但两组根治性治疗后复发风险相似(HR 1.04,95%CI 0.75-1.43;P=0.83)。提示MRI时代GG2诊断增加可能部分反映重分类而非更具侵袭性疾病。
要点
- MRI靶向活检GG2的复发风险与系统活检GG1相当(HR 1.04)
- GG1组中位至治疗时间31个月,显著长于GG2组的4个月
- 部分MRI时代GG2诊断增加可能为重分类,需改进风险分层筛选主动监测候选者
核心结论
- MRI靶向活检检出的GG2前列腺癌根治性治疗后复发风险与系统活检检出的GG1相似。
- 尽管GG2组更倾向于接受根治性治疗,但复发风险无显著差异。
- MRI时代GG2诊断增加可能部分反映重分类而非更具侵袭性疾病。
研究设计与样本
- 回顾性研究,使用大型三级中心注册数据库(HUS Acamedic data lake)。
- 纳入1993至2019年间系统活检检出GG1前列腺癌患者3317例和MRI靶向活检检出GG2患者554例。
- 评估根治性治疗风险和复发风险,采用Kaplan-Meier曲线和Cox比例风险回归。
主要发现
- 系统活检GG1组中位至治疗时间31个月,显著长于靶向活检GG2组的4个月(P<0.0001)。
- 两组根治性治疗后复发风险相似(HR 1.04,95%CI 0.75-1.43;P=0.83)。
临床怎么用
- MRI靶向活检GG2患者复发风险与系统活检GG1相当,提示部分GG2可考虑主动监测。
- 需改进风险分层以识别适合主动监测的MRI时代GG2患者。
局限性
- 回顾性研究设计。
- 单中心注册数据。
- 未报告主动监测的具体纳入标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies. MATERIALS AND METHODS: We performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence. RESULTS: Patients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83). CONCLUSION: Men diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.
引用
- Batouche AO, Czeizler E, Lehto TP, et al. Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer. BJU Int. 2025. PMID: 41392525. doi:10.1111/bju.70109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。